Fellowship Title: | Cell Therapy and Regenerative Medicine |
Division: | Hematology |
Fellowship Type: | Clinical and Research |
Supervisor: | Arjun Law |
Duration: | 1 year |
Application Open and Close Date: | Recruitment is ongoing |
Anticipated Start Date(s): | Dependent on availability |
Number of position(s) per year: | 1 |
Description: | This is a unique blended research (25%) and clinical (75% supervised) fellowship between malignant hematology and immune cell therapy. The successful applicant will develop expertise in dealing with patients with hematologic malignancies and all aspects of their care, with a focus on treatment with immune cell therapy interventions including the requirement of bridging therapies and conditioning regimens. The trainee will learn to manage acute complications of immune effector cell therapy; including cytokine release syndrome and immune cellular therapy associated neurotoxicity syndromes. The trainee should have prior experience in allogeneic transplantation, extending these skills to IEC therapy and will become part of a multidisplinary team communicating with other disciplines, e.g. surgical or radiation oncology, psychosocial oncology, in the multidisciplinary treatment of patients. This fellowship will provide experience in managing the rigorous regulatory stipulations for safely conducting cellular therapy clinical trials (FACT and Health Canada accreditation among others).The successful applicant will participate in in-house committees (such as the Immune Effector Cellular Therapy Operations Committee) to recognize different aspects of building an effective program. The trainee will also actively participate in clinical trials, including design and implementation stages.
Majority of their research time will be dedicated to a research project that will be presenting a national/international meeting. At the end of this fellowship, the trainee should have completed at least one peer-reviewed publication. |
Contact Name: | Lianne Mulveney |
Role: | Fellowship Coordinator |
Telephone: | 416-946-4501 x 5429 |
E-mail: | Lianne.Mulveney@uhn.ca |
Fellowship Title: | Hematology - OCC |
Division: | Hematology |
Fellowship Type: | Clinical |
Duration: | 1 - 2 years |
Anticipated Start Date(s): | Revolving. At least 9 months from start date for foreign trainees. |
Number of position(s) per year: | 1 -2 |
Description: | Fellowships in Hematology at the Sunnybrook Odette Cancer Centre (OCC) are available to candidates who have completed their formal Hematology training in their home country. The purpose of the fellowship is to provide additional clinical and research training for those interested in pursuing an academic career. Areas of research and clinical focus are available in one or more of the following areas: MDS, lymphoma, myeloma and leukemia. Supervision is provided by the one or more of the malignant hematology staff. Opportunities to apply for peer reviewed research funding and graduate degree program are available and encouraged. |
Contact Name: | Cher Kazdan |
Role: | Fellowship Administrator |
E-mail: | Cher.Kazdan@sunnybrook.ca |
Mailing Address: | Sunnybrook Health Sciences Centre 2075 Bayview Avenue, T2-023 Toronto, ON M4N 3M5 |
Fellowship Title: | Leukemia |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Aaron Schimmer, Dr. Andre Schuh, Dr. Mark Minden, Dr. Karen Yee, Dr. Steven Chan, Dr. Vikas Gupta, Dr. Dawn Sheppard |
Duration: | 1- year period with an opportunity to extend to 2 years |
Anticipated Start Date(s): | July or January |
Number of position(s) per year: | 1 or 2 (depending on availability) |
Description: | The Princess Margaret Cancer Centre Leukemia program is the largest provider of Leukemia services in Canada, and one of the largest in North America. The program is composed of a multidisciplinary team of physicians, nurses, advanced nurse practitioners, physiotherapists, social workers, and research coordinators dedicated to the treatment of patients with Leukemias and related disorders. Fellows will gain clinical experience in the care of patients with acute leukemia and related disorders. Fellows will have the opportunity to participate in clinical research projects, design of clinical trial under the supervision of leukemia physicians, learn the principles of conducting clinical research, and participate in program’s academic activities. Depending on the interest and career goals of the candidate, opportunities will be available for pursuing a combined fellowship in the Leukemia and Allogeneic Stem Cell Transplantation or a translational/laboratory-based research fellowship related to leukemia/MDS/MPN. Candidates must have completed subspecialty training in medical oncology or hematology and be eligible for licensure with the College of Physicians and Surgeons of Ontario. Overseas candidates should have Canadian equivalent training in the above disciplines. |
Contact Name: | Dr. Vikas Gupta, MD, FRCP, FRCPath |
Role: | Fellowship Program Head |
Telephone: | (416) 946-4521 |
E-mail: | vikas.gupta@uhn.ca |
Mailing Address: | Princess Margaret Cancer Centre 610 University Avenue, 5-303C Toronto, ON CANADA M5G 2M9 |
Fellowship Title: | Leukemia & Myeloproliferative Neoplasms - UHN |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Vikas Gupta |
Duration: | 2 years |
Application Open and Close Date: | N/A |
Anticipated Start Date(s): | July 1 each year |
Number of position(s) per year: | N/A |
Description: | Fellows who have completed residency in medical oncology or hematology have the opportunity to participle in a clinical research fellowship in the treatment at the Division of Hematology at Princess Margaret Cancer Centre. Fellows’ participation actively in the planning, coordination and implementation of protocol development, in selected protocols mounted by the Myeloproliferative Neoplasms Program. This would include working in the lab, writing letters of intent and protocols, analyzing trial data, presenting results in local/national/international meetings, and preparing final peer-reviewed manuscripts for publication. |
Contact Name: | Lianna Mulveney |
Role: | UHN Medical Oncology & Hematology Fellowship Administrator |
Telephone: | 416-946-4501 ext. 5429 |
E-mail: | Lianne.Mulveney@uhn.ca |
Fellowship Title: | Lymphoma - UHN |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Chloe Yang |
Duration: | 2 years |
Application Open and Close Date: | N/A |
Anticipated Start Date(s): | July 1 each year |
Number of position(s) per year: | N/A |
Description: | Fellows have the opportunity to participate in a clinical research fellowship focusing on the treatment of people with cancer using high-dose therapy and autologous and allogeneic stem cell transplantation at the Division of Hematology at Princess Margaret Cancer Centre. |
Contact Name: | Lianna Mulveney |
Role: | UHN Medical Oncology & Hematology Fellowship Administrator |
Telephone: | 416-946-4501 ext. 5429 |
E-mail: | Lianne.Mulveney@uhn.ca |
Fellowship Title: | Maternal Fetal Hematology |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Nadine Shehata |
Duration: | 2 years |
Application Open and Close Date: | August 1 |
Anticipated Start Date(s): | July 1 |
Number of position(s) per year: | 1 |
Description: | The Medical Disorders of Pregnancy Program at the University of Toronto is an internationally acknowledged program recognized for its excellence in patient care, medical education and research. This program, based predominantly at Mount Sinai Hospital in Toronto, exposes trainees to high patient volumes, a coordinated approach to patient management and research opportunities with world-class Maternal Fetal Medicine specialists. This fellowship in Maternal/Fetal Hematology is intended for highly motivated academic physicians who have completed basic Hematology/Obstetrics training and wish to pursue clinical and scholarly excellence in the approach and management of women with hematological disorders in pregnancy. The Medical Disorders in Pregnancy Program at the University of Toronto provides a wide breadth of exposure to clinical hematological disorders peripartum including immune disorders, hemoglobinopathies, thromboembolism, myeloproliferative disorders, malignancies, and hemostasis as well as laboratory based exposure including the investigation and management of hemolytic disease of the fetus and newborn and fetal/neonatal alloimmune thrombocytopenia. The fellow is strongly encouraged to enroll in a graduate program in research, medical education or quality improvement. The successful candidate will have at least 50% time dedicated to their academic activities. It is the intent of the fellowship that the successful candidate will become a future global leader in academic maternal/fetal hematology. |
Contact Name: | Lianna Mulveney |
Role: | UHN Medical Oncology & Hematology Fellowship Administrator |
Telephone: | 416-946-4501 ext. 5429 |
E-mail: | Lianne.Mulveney@uhn.ca |
Fellowship Title: | Maternal Fetal Hematology Program - MSH/SMH/UHN |
Division: | Hematology |
Fellowship Type: | Clinical and Research |
Supervisor: | Nadine Shehata |
Duration: | 2 years |
Anticipated Start Date(s): | July 1, 2020 |
Description: | The Medical Disorders of Pregnancy Program at the University of Toronto is an internationally acknowledged program recognized for its excellence in patient care, medical education and research. This program, based predominantly at Mount Sinai Hospital in Toronto, exposes trainees to high patient volumes, a coordinated approach to patient management and research opportunities with world-class Maternal Fetal Medicine specialists.
This fellowship in Maternal/Fetal Hematology is intended for highly motivated academic physicians who have completed basic Hematology training and wish to pursue clinical and scholarly excellence in the approach and management of women with hematological disorders in pregnancy. The Medical Disorders in Pregnancy Program at the University of Toronto provides a wide breadth of exposure to clinical hematological disorders peripartum including immune disorders, hemoglobinopathies, thromboembolism, myeloproliferative disorders, malignancies, and hemostasis as well as laboratory based exposure including the investigation and management of hemolytic disease of the fetus and newborn and fetal/neonatal alloimmune thrombocytopenia. The fellow is strongly encouraged to enroll in a graduate program in research, medical education or quality improvement. The successful candidate will have at least 50% time dedicated to their academic activities. It is the intent of the fellowship that the successful candidate will become a future global leader in academic maternal/fetal hematology. Minimum Requirements Subspecialty training in hematology and eligible for licensure through College of Physicians and Surgeons of Ontario. How to Apply: Please submit Curriculum Vitae, Letter of Intent and Three Letters of Recommendation to Fellowship Administrator via email. |
Contact Name: | Lianne Mulveney |
Role: | UHN Medical Oncology & Hematology Fellowship Administrator |
E-mail: | Lianne.Mulveney@uhn.ca |
Fellowship Title: | Myeloma and Mature B-Cell Disorders |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Anca Prica |
Duration: | 1 year, with option to renew for 2nd year |
Application Open and Close Date: | Ongoing |
Anticipated Start Date(s): | Start dates negotiable |
Number of position(s) per year: | Variable |
Description: | We are currently offering a clinical research fellowship in the treatment of multiple myeloma and associated mature B-cell lymphoproliferative disorders at the Princess Margaret Cancer Centre (PM). The Princess Margaret Myeloma Group (including six dedicated myeloma/lymphoma physicians) sees approximately 300 new patients and performs autotransplants in over 200 patients per year. Princess Margaret Cancer Centre is the largest myeloma centre in Canada and receives patient referrals from across the country and internationally. The group is actively involved in clinical and laboratory research with international collaborations. Fellows will have the opportunity to gain clinical experience in the care of patients with myeloma and related disorders, including application of the principles of intensive therapy and stem cell transplantation as well as the use of novel agents in drug development. Fellows will have the opportunity to participate in clinical investigation (writing/directing study protocols, participation with the NCIC, applying for grant support, etc). Depending upon candidate interest, opportunities in laboratory research and/or patient/faculty education and supportive care in mature B cell disorders are available. Candidates must be eligible for registration with the College of Physicians and Surgeons of Ontario and hold subspecialty certification in Hematology or Medical Oncology from the Royal College of Physicians and Surgeons of Canada. |
Contact Name: | Dr. Anca Prica |
Role: | Staff Hematologist Lymphoma/Myeloma Site Group |
Telephone: | 416-946-2249 |
E-mail: | Anca.prica@uhn.ca |
Mailing Address: | Dept of Medical Onc & Hematology Princess Margaret Cancer Centre 610 University Avenue, OPG 6TH FLOOR Toronto, ON M5G 2M9 Tel: 416-946-2249; Fax: 416-946-4407 |
Fellowship Title: | Myeloproliferative Neoplasms |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Vikas Gupta |
Duration: | 1 year with opportunity to extend to 2 years |
Anticipated Start Date(s): | July and January |
Number of position(s) per year: | 1 (or depending on availability) |
Description: | The Elizabeth and Tony Comper MPN program at Princess Margaret Cancer Center offers a unique opportunity for a clinical or translational fellowship in MPN. The MPN program at Princess Margaret is the largest in Canada, and the focus of the program is to excel in basic, translational and clinical research related to MPN and related disorders. A recent philanthropic donation has further led to strengthening the infra-structure of this program. MPN program works closely with a team of leukemia and transplant physicians, and there will be opportunity to train in other aspects of myeloid malignancies and allogeneic transplantation depending on candidate’s interest and career goals. We are actively involved in clinical, laboratory, and translational research, and have a large portfolio of clinical trials. In addition to gaining clinical experience, fellows will have the opportunity to participate in clinical and translational research projects, design of clinical trials, learn the principles of conducting research, and participate in the academic activities of the program. The expected start date is July or January, but is negotiable. Candidates must have completed training in internal medicine, and sub-specialty training in hematology or medical oncology. Overseas candidates should have Canadian equivalent training in the above disciplines. |
Contact Name: | Dr. Vikas Gupta, MD, FRCP, FRCPath |
Role: | Fellowship Programs Head |
Telephone: | (416) 946-4521 |
E-mail: | vikas.gupta@uhn.ca |
Mailing Address: | Princess Margaret Cancer Centre 610 University Avenue, 5-303C Toronto, ON CANADA M5G 2M9 |
Fellowship Title: | The James Drewry Stewart Fellowship in
Multiple Myeloma and Malignant Hematology - SMH |
Division: | Hematology |
Fellowship Type: | Clinical |
Supervisor: | Dr. Lisa Hicks and Dr. Martina Trinkaus |
Duration: | 1 year |
Application Open and Close Date: | Feb 1 with close date June 30 |
Anticipated Start Date(s): | July 1 |
Description: | The James Drewry Stewart Fellowship in Multiple Myeloma and Malignant Hematology will provide financial assistance in the form of fellowship grants to oncology trainees at St. Michael's Hospital who have completed their core training in oncology and are seeking additional clinical training in myeloma and other blood cancers. Background: Multiple myeloma and lymphoma are the most common types of blood cancers and the fifth most common cause of cancer overall. Multiple myeloma in particular is a very complex disease that can cause major complications for patients including bone fractures, pain crises, kidney failure and dangerously high blood calcium levels. It is also one of the cancers for which treatment options have advanced the most quickly in the last five years. As a result, expert, patient-centered care for patients with myeloma is essential, and not always readily available. In the community setting, myeloma is frequently managed by medical oncologists rather than by hematologists. Yet, many oncologists receive relatively little training in this specialized cancer. Most oncology training is focused on more common cancers such as breast, colon and lung cancer, and the complexities of myeloma may not be addressed. There is a growing need for advanced clinical training in malignant hematology, and in particular for clinical training in multiple myeloma. |
Contact Name: | Maryana Ghazula |
Role: | Administrator |
Telephone: | 416-864-5632 |
E-mail: | GazhulaM@smh.ca |
Mailing Address: | St. Michael's Hospital, 30 Bond St, Room 2-084, Toronto ON M5B 1W8 |